MétaCan
Menu
← Back to cohort
Record W2616560686 · doi:10.1093/eurheartj/ehx275

Reduction of LDL-C-related residual cardiovascular risk with ezetimibe: are mechanistic considerations warranted in practice?

2017· letter· en· W2616560686 on OpenAlexaff
Karin H. Humphries, G.B. John Mancini

Bibliographic record

VenueEuropean Heart Journal · 2017
Typeletter
Languageen
FieldMedicine
TopicLipoproteins and Cardiovascular Health
Canadian institutionsUniversity of British Columbia
Fundersnot available
KeywordsMedicineEzetimibeResidual riskLdl cholesterolCardiologyAtherosclerotic cardiovascular diseaseResidualInternal medicineReduction (mathematics)Intensive care medicineCholesterolDisease

Abstract

fetched live from OpenAlex

This editorial refers to ‘Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial’†, by N. Hagiwara et al., on page 2264. High levels of LDL cholesterol are causally linked to the risk of developing atherosclerotic cardiovascular disease (ASCVD). Reducing LDL cholesterol levels has been demonstrated to result in a reduction in cardiovascular events, with supporting evidence from both epidemiological studies and numerous randomized clinical trials. A recent meta-analysis by the Cholesterol Treatment Trialists’ Collaboration of 174 000 men and women demonstrated a relative risk reduction in major cardiovascular events of 22% in men and 16% in women with every 1.0 mmol/L (38.6 mg/dL) reduction in LDL cholesterol with a statin.1 This meta-analysis demonstrated that for every 1% reduction in LDL cholesterol, the risk of ASCVD events was reduced by 1%.2 On average, statins reduce LDL cholesterol levels between 40% and 60%, prompting the question of whether further reduction, beyond that achieved by high-intensity statins, would translate to further reductions in ASCVD events. The IMPROVE-IT trial3 addressed this question in 18 144 subjects, hospitalized for acute coronary syndromes, randomized to simvastatin (40 mg) plus ezetimibe (10 mg) or simvastatin (40 mg) alone. Ezetimibe reduces absorption of cholesterol from the intestine (see Figure 1) by targeting the Niemann–Pick C1-like 1 protein. From a baseline LDL cholesterol level of 2.4 mmol/L (93.8 mg/dL), the simvastatin + ezetimibe group declined to 1.4 mmol/L (53.2 mg/dL), while the statin monotherapy groups declined to 1.8 mmol/L (69.9 mg/dL). This 24% greater reduction in LDL cholesterol with ezetimibe resulted in a 6% relative reduction in cardiovascular death, major coronary event, or non-fatal stroke [hazard ratio (HR) 0.936, 95% confidence interval (CI) 0.89–0.99].

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.004
metaresearch head score (Gemma)0.032
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Editorial · Consensus signal: none
Teacher disagreement score0.030
Threshold uncertainty score0.023

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0040.032
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0030.001
Bibliometrics0.0010.001
Science and technology studies0.0020.003
Scholarly communication0.0040.005
Open science0.0020.001
Research integrity0.0300.036
Insufficient payload (model declined to judge)0.0060.004

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.034
GPT teacher head0.281
Teacher spread0.247 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreEditorial

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2017
Admission routes1
Has abstractno

Explore more

Same venueEuropean Heart Journal→Same topicLipoproteins and Cardiovascular Health→French-language works237,207→